Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
We present a 'call to action' on the need for clinical alignment on terminology in the field and recommend the term 'long-term management' be adopted as the most appropriate in the context of this manuscript. This expert opinion report provides a detailed review of the limited evidence available regarding long-term use of topical therapies for the management of psoriasis, alongside our key considerations and recommendations to assist dermatologists with the implementation of topicals as part of long-term management strategies. Long-term management should be considered mandatory to ensure patients receive appropriate proact...
This cross-sectional study using data from the Dermatology Clinical Effectiveness Research Network assesses whether the frequency of “not relevant” responses on the Dermatology Life Quality Index (DLQI) is associated with sociodemographic characteristics of patients with psoriasis.
The article Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents, written by Vibeke Strand, Joao Gon çalves, Timothy P. Hickling, Heather E. Jones, Lisa Marshall and John D. Isaacs, was originally published Online First without Open Access.
This study was registered on May 15,2019 at ClinicalTrials.gov with the identifier numberNCT03952676.
Psoriasis is a chronic, systemic immune-mediated disease characterized by development of erythematous, indurated, scaly, pruritic plaques on the skin. Psoriasis is frequently associated to comorbidities, including psoriatic arthritis, cardiovascular diseases, diabetes mellitus, obesity, non-alcoholic fatty liver disease, and inflammatory bowel diseases. In this review, we discuss the pathophysiological relationship between psoriasis and cardio-metabolic comorbidities and the importance of therapeutic strategies to reduce systemic inflammation in patients with moderate-to-severe psoriasis. Pathogenesis of psoriasis and its ...
Abstract The stilbene tapinarof is a drug used to treat psoriasis and atopic dermatitis. Efficacy is thought to arise from its regulation of the aryl hydrocarbon receptor and nuclear factor erythroid 2-related factor 2 signaling pathways, which have also been linked to the severity of inflammatory bowel diseases. Tapinarof is produced by the gammaproteobacterial Photorhabdus genus, which infects insects and humans. Consequently, Photorhabdus represents a model to probe tapinarof structural and functional transformations. Here, we demonstrate that Photorhabdus transforms tapinarof into novel drug metabolism product...
This review explores established and emerging clinical indications for methotrexate in dermatological conditions, including psoriasis, blistering diseases, chronic urticaria, slceroderma, and more.Skin Therapy Letter
This article is protected by copyright. All rights reserved. PMID: 32092146 [PubMed - as supplied by publisher]
ConclusionsThe clinical relevance of the effective management of adverse events in this case demonstrates the opportunity to enable patients to remain on therapy, thereby maintaining long-term response and improving overall outcomes.
This article is categorized under: Biological Mechanisms> Metabolism Translational, Genomic, and Systems Medicine> Translational Medicine Physiology> Mammalian Physiology in Health and Disease